Mark Diamond
Hematology & Oncology · Philadelphia, PANPI 1477870442
Payments from drug & device makers
Across 39 payments — averaging $11,462 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$179K
- Amgen$146K
- Otsuka Pharmaceutical Co., Ltd.$97K
- Taiho Oncology, Inc.$23K
- Boehringer Ingelheim Pharma GmbH & Co.kg$2K
- Beigene USA, Inc.$58
- plus $70 from 4 others
What the payments were for
- Food & beverage$128100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 10 | $179,418 |
| Amgen | 4 | $145,824 |
| Otsuka Pharmaceutical Co., Ltd. | 10 | $96,730 |
| Taiho Oncology, Inc. | 8 | $22,980 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $1,924 |
| Beigene USA, Inc. | 2 | $58 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Beone Medicines USA, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
How this compares
$447,004 in reported general payments places this provider in the 85th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 24 | $320 |
| Oxycodone Hcl | 17 | $199 |
| Prochlorperazine Maleate | 17 | $158 |
| Dexamethasone | 13 | $142 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Philadelphia
- Stephen BagleyPhiladelphia$13.1M
- Stephen SchusterPhiladelphia$9.5M
- Pooja GhataliaPhiladelphia$8.3M
- Corey LangerPhiladelphia$7.7M
- Alfred GarfallPhiladelphia$7.6M
- Charu AggarwalPhiladelphia$7M
- Marcela MausPhiladelphia$4.4M
- Catherine LaiPhiladelphia$3.8M
- James StevensonPhiladelphia$3.4M
- Tara MitchellPhiladelphia$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.